Table of Contents

• Cardiac Screening Methods Miss Half of Heart Attack Risks: New Study
  • understanding the Limitations of Current Cardiac Risk Assessment
    • What are ASCVD and PREVENT?
  • Risk Scores Often Underestimate Individual Danger
    • Key findings of the Mount Sinai Study
  • Implications for Cardiac Care and Future Research
  • Key Takeaways

understanding the Limitations of Current Cardiac Risk Assessment

The team evaluated the accuracy of the widely used atherosclerotic cardiovascular disease (ASCVD) risk score and a newer tool known as PREVENT. PREVENT incorporates additional variables and is designed to offer a broader picture of cardiovascular risk alongside screening for symptoms.

What are ASCVD and PREVENT?

Atherosclerotic Cardiovascular Disease (ASCVD) refers to a buildup of plaques in the arteries, leading to potential heart attack, stroke, or peripheral artery disease. The ASCVD risk score estimates a person’s 10-year risk of experiencing a cardiovascular event based on factors like age, gender, cholesterol levels, blood pressure, and smoking status.While widely used, it has known limitations.

PREVENT is a more extensive risk assessment tool. It builds upon the ASCVD score by incorporating additional biomarkers and clinical data to provide a more individualized risk profile. The goal of PREVENT is to identify individuals who may be missed by customary risk scores.

Risk Scores Often Underestimate Individual Danger

“Our research shows that population-based risk tools often fail to reflect the true risk for many individual patients,” says corresponding author Amir Ahmadi, MD, Clinical Associate Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount sinai. “If we had seen these patients just two days before their heart attack, nearly half would NOT have been flagged as high-risk by these standard assessments.”

Key findings of the Mount Sinai Study

• The study found that nearly 50% of patients who experienced a heart attack were not identified as high-risk by the ASCVD risk score.
• PREVENT showed improved accuracy, but still missed a significant portion of at-risk individuals.
• The discrepancy highlights the need for more personalized and comprehensive cardiac risk assessment strategies.

Implications for Cardiac Care and Future Research

These findings suggest that relying solely on population-based risk scores can lead to underestimation of individual risk and delayed intervention.This could mean that people who could benefit from preventative measures – like lifestyle changes or medication – are not receiving them in a timely manner.

Further research is needed to refine risk assessment tools and identify additional biomarkers that can improve the accuracy of predicting heart attacks. The development of more personalized approaches to cardiac care is crucial for improving outcomes and saving lives.

Key Takeaways

• current cardiac risk scores, like the ASCVD score, are not always accurate in predicting heart attacks.
• Newer tools like PREVENT offer improvements but are not foolproof.
• Personalized risk assessment is essential for identifying individuals who need preventative care.
• More research is needed to develop more accurate and comprehensive
  

  More on this

  • Can Testosterone Screening Fix the Crisis of Masculinity?
  • Allergy Medication Recalled Due to Life-Threatening Contamination